A surgeon in a provincial hospital threads instruments through a single small incision, steering a master-slave robot whose maker is not from Silicon Valley or Sunnyvale. A decade ago this scene was almost unthinkable outside a handful of imported systems. Today, the console could be built an hour's drive from the operating theatre.
On 25 August 2026, China reached a quiet milestone: 19 registration certificates for laparoscopic surgical robots (腹腔镜手术机器人), spanning 15 registrants and about 12 brand systems. The supply structure that Intuitive Surgical's da Vinci once dominated absolutely now includes a cohort of Chinese companies with complete master-slave systems.
From "when will they be approved" to "how many specialties"
For years the domestic industry's anxious question was simple — when will Chinese surgical robots get cleared? The answer is now quantitative. Of the 19 certificates, 18 carry the domestic-device "Guo Xie Zhu Zhun" mark; one is imported. The newest went to United Imaging Surgical (uSurgRobot DS 2000, cleared 29 July 2026), with indications covering urology, gynecology, general surgery and thoracic surgery.
Edge Medical's single-port breakthrough
Shenzhen-based Edge Medical (精锋医疗, HKEX: 02675) sits at the centre of the shift. On 19 March 2026 its Edge Single-Port Robot (SP1000) won an NMPA registration change adding thoracic surgery, giving it coverage across gynecology, urology, general surgery and thoracic — the first domestic single-port system cleared for all four major disciplines. Earlier the SP1000 had logged over 2,000 clinical cases across the first three.
A month earlier, in March 2026, Edge's MSP2000 — a single/multi-port integrated laparoscopic robot — received NMPA approval as, per the company, the world's first approved system merging both modes on one platform. A hospital buys one cart and swaps arms to switch between multi-port and single-port procedures, instead of buying two separate systems.
Why single-port matters
Single-port surgery enters through one incision rather than several, reducing trauma, speeding recovery and improving cosmetics. But the engineering bar is high: instruments must deploy and retract through a tight channel, and the surgeon needs consistent feel across different anatomy. Thoracic work is the hardest — confined space, rib obstructions, limited instrument articulation. Edge's thoracic clearance signals the system held up in the most demanding scenario.
Going overseas faster than at home
The localization story is also an export story. Edge Medical reported 2025 full-year revenue of 456 million yuan (≈ US$64M / HK$502M), up 184.8%, with overseas business revenue of 272 million yuan (≈ US$38M / HK$299M) — 59.7% of the total. Cumulative orders reached 119 units and cumulative installations 100, of which 54 were overseas versus 46 in China: the first time overseas installs beat domestic.
Regulatory doors opened in Europe via CE certification (MDR) for the MP1000 (March 2025) and SP1000/MSP2000 (October 2025). By end-2025 Edge held MP1000 registrations across 22 jurisdictions covering 55 countries and regions. Installations run in Germany, France, Italy, Spain and Poland.
The wider field
Edge is one of three domestic laparoscopic leaders alongside MicroPort MedBot (微创机器人) and Sizhe Rui (思哲睿). MicroPort's Toumai (图迈) single-port passed 200 global commercial orders across nearly 50 countries with close to 130 systems installed by early 2026. Intuitive Surgical's da Vinci still leads globally; its da Vinci 5 passed 1,400 installs worldwide by Q1 2026. The next competitive axis is not approval but utilisation — how many specialties, procedures and annual surgeries one machine sustains.
From certificates to the operating theatre
Approval is the start, not the finish. The harder bottleneck is utilisation: a robot that sits idle between rare procedures is a depreciating asset, while one that runs daily across urology, gynaecology, general and thoracic cases pays for itself. That is why single-port coverage of all four disciplines — and the MSP2000's single-cart dual-mode design — matters commercially: it lets a mid-size hospital justify one purchase instead of two. Surgeon training is the other gate. Master-slave systems feel unfamiliar, and hospitals adopting domestic robots report a learning curve measured in procedures, not hours. The companies winning the next phase will be those pairing the device with training, service and procedural data, not those that merely hold the most certificates.
What readers can do now
- Hospital procurement teams should weigh total procedure cost, not just list price: single/multi-port integration (MSP2000) can cut capital outlay for smaller hospitals.
- Clinicians evaluating robots should check indicated specialties per NMPA/CE certificate — "surgical robot" approvals differ sharply by discipline.
- Investors tracking China medtech can use installation count (not certificate count) as the real adoption metric; Edge's overseas > domestic flip is the signal to watch.
Honest limitations
Certificate and sales figures come from industry trackers (MedRobot) and company disclosures reprinted in trade media; independent audit of the 100-installation and 54-overseas numbers is not public. "World's first" claims for MSP2000 are company-stated. This article covers laparoscopic (abdominal/thoracic) surgical robots only; it excludes orthopaedic, radiological and bronchoscopic systems, and it does not assess clinical outcomes or reimbursement policy by region.